Imagine a landscape where a rare cancer, often resistant to repeated treatments, finally meets a game-changing solution. On December 4, this became reality as the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel, marketed as Breyanzi by Juno Therapeutics, as the first
What if a hidden enemy within the body, silently damaging vital organs, could finally be dismantled with precision? For thousands battling rare diseases like AL amyloidosis, where toxic protein deposits wreak havoc on the heart and kidneys, this prospect is no longer a distant dream. A
Picture a medical landscape where treatments can slip past the body's toughest defenses, delivering healing payloads directly to diseased cells without harming the surrounding healthy tissue. This isn't science fiction but the tantalizing promise of engineered exosomes—tiny biological couriers that
Imagine a world where a single treatment could manage type 2 diabetes or obesity for months at a time, freeing patients from the burden of daily medications and the frustrating cycle of weight regain. This isn’t a distant dream but a potential reality being shaped by Junevity, a biotechnology
What if a single batch of cells could save thousands of lives without the wait and expense of custom-made treatments? This isn’t a distant dream but a tangible reality unfolding in the realm of allogeneic cell therapy, where “off-the-shelf” solutions derived from donor cells are poised to
What if the complex journey of turning a groundbreaking biologic into a life-saving therapy could be transformed into a streamlined, efficient process? In a world where biopharmaceutical development faces unprecedented challenges, a powerful collaboration between Rentschler Biopharma and Coriolis
